Perry Karsen Net Worth
The estimated Net Worth of Perry A Karsen is at least $24.1 Million dollars as of 5 June 2017. Mr. Karsen owns over 10,000 units of Intellia Therapeutics stock worth over $128,200 and over the last 8 years he sold NTLA stock worth over $23,569,610. In addition, he makes $428,076 as Independent Chairman of the Board at Intellia Therapeutics.
Mr. Karsen NTLA stock SEC Form 4 insider trading
Perry has made over 26 trades of the Intellia Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of NTLA stock worth $34,600 on 5 June 2017.
The largest trade he’s ever made was exercising 118,008 units of Intellia Therapeutics stock on 2 August 2013 worth over $5,312,720. On average, Perry trades about 8,251 units every 16 days since 2012. As of 5 June 2017 he still owns at least 10,000 units of Intellia Therapeutics stock.
You can see the complete history of Mr. Karsen stock trades at the bottom of the page.
Perry Karsen biography
Perry A. Karsen is an Independent Chairman of the Board of the Company. Mr. Karsen is the Chairman of the Board of the company. From May 2013 to December 2015, Mr. Karsen served as the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation, a global biopharmaceutical company. Mr. Karsen served as chief operations officer and executive vice president of Celgene from July 2010 to May 2013, and as senior vice president and head of worldwide business development of Celgene from 2004 to 2009. Between February 2009 and July 2010, Mr. Karsen was chif executive officer of Pearl Therapeutics, Inc., a privately held biotechnology company that was subsequently acquired by AstraZeneca plc. Prior to his tenure with Celgene, Mr. Karsen held executive positions at Human Genome Sciences, Inc., a biopharmaceutical company subsequently acquired by GlaxoSmithKline, Bristol-Myers Squibb Co., a biopharmaceutical company, Genentech, Inc., a member of the Roche Group, and Abbott. In addition, Mr. Karsen previously served as a general partner at Pequot Ventures, a venture capital firm. Mr. Karsen serves on the board of directors of the following public companies: OncoMed Pharmaceuticals, Inc., Jounce Therapeutics, Inc. and Voyager Therapeutics, Inc. Within the last five years, he has served on the board of directors of Agios Pharmaceuticals, Inc., Navidea Biopharmaceuticals, Inc. and Alliqua BioMedical, Inc. He also serves on the board of directors of Pliant Therapeutics, Inc., the Gladstone Foundationand the Sonoma Land Trust. He is a past member of the board of directors and a past member of the executive committee of the Biotechnology Innovation Organization and the board of directors of the Alliance for Regenerative Medicine. Mr. Karsen received a masters of management degree from Northwestern University’s Kellogg Graduate School of Management, a masters of arts in teaching of biology from Duke University and a B.S. in biological sciences from the University of Illinois, Urbana-Champaign.
What is the salary of Perry Karsen?
As the Independent Chairman of the Board of Intellia Therapeutics, the total compensation of Perry Karsen at Intellia Therapeutics is $428,076. There are 5 executives at Intellia Therapeutics getting paid more, with John Leonard having the highest compensation of $9,708,330.
How old is Perry Karsen?
Perry Karsen is 64, he’s been the Independent Chairman of the Board of Intellia Therapeutics since 2017. There are 1 older and 8 younger executives at Intellia Therapeutics. The oldest executive at Intellia Therapeutics, Inc. is Jesse Goodman, 67, who is the Independent Director.
What’s Perry Karsen’s mailing address?
Perry’s mailing address filed with the SEC is C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT, NJ, 07901.
Insider trading at Intellia Therapeutics
Over the last 4 years, insiders at Intellia Therapeutics have traded over $56,776,555 worth of Intellia Therapeutics stock and bought 1,285,277 units worth $23,117,886 . The most active insider traders include Bros. Advisors Lpbaker Feli…, Carl L Gordon, and Jean Francois Formela. On average, Intellia Therapeutics executives and independent directors trade stock every 54 days with the average trade being worth of $2,769,150. The most recent stock trade was executed by Andrew Schiermeier on 6 March 2019, trading 7,500 units of NTLA stock currently worth $117,900.
What does Intellia Therapeutics do?
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
What does Intellia Therapeutics’s logo look like?
Complete history of Mr. Karsen stock trades at Agios Pharmaceuticals, Celgene, Intellia Therapeutics, Jounce Therapeutics, Voyager Therapeutics, and Navidea Biopharmaceuticals
Intellia Therapeutics executives and stock owners
Intellia Therapeutics executives and other stock owners filed with the SEC include:
- John Leonard, President, Chief Executive Officer, Director
- Andrew Schiermeier, Executive Vice President -Corporate Strategy and Development
- Jose Rivera, Executive Vice President, General Counsel
- Glenn Goddard, Chief Financial Officer
- Jesse Goodman, Independent Director
- Perry Karsen, Independent Chairman of the Board
- Caroline Dorsa, Independent Director
- Frank Verwiel, Independent Director
- Jean-Francois Formela, Independent Director
- Frederick Cohen, Independent Director
- Lina Li, Senior Manager, Investor Relations
- Laura Sepp-Lorenzino, Executive Vice President, Chief Scientific Officer
- Carl L Gordon, Director
- Institutes For Bio Medical …,
- Advisors Llc Orbi Med Capit…,
- Graeme Bell, EVP, Chief Financial Officer
- Venture Associates Ix, L.P….,
- Nicole Heifner, SVP, Accounting
- Thomas M. Barnes, SVP, R&D eXtellia
- Therapeutics Holdco, Llc Ca…,
- Nessan Bermingham, President & CEO
- David V Morrissey, SVP, Platform & Delivery Tech
- Venture Fund Ix, L.P.Atlas …,
- Holdings (Private) Ltd Full…,
- Rachel E. Haurwitz, Director
- Bros. Advisors Lpbaker Feli…,
- Moncef Slaoui, Director
- Biosciences, Inc. Caribou,
- Fred E Cohen, Director
